Global influenza spending is being shaped by a $5.0 billion influenza diagnostics market in 2023 alongside a $3.6 billion influenza vaccine market, yet the real-world impact is measured in how much vaccination cuts illness and hospital risk. Cochrane pooled evidence points to a 37% reduction in influenza illness for vaccinated people, while some cohort claims research finds a 2.5% lower probability of hospitalization. Pricing, wastage assumptions, and ICER ranges move in the same direction but not always the way you might expect, making this a dataset worth reading closely.
Key Takeaways
- $5.0 billion global influenza diagnostics market size in 2023, supporting flu surveillance and testing expenditures.
- $3.6 billion global influenza vaccine market size in 2023 (with growth forecasts tied to seasonal demand and pandemic preparedness).
- $7.3 billion global influenza vaccine market size estimate for 2024 in a segment-focused industry forecast.
- 37% reduction in influenza illness among vaccinated individuals compared with unvaccinated in a pooled estimate across randomized and observational studies summarized by the Cochrane review evidence base.
- 39% reduction in risk of influenza-related medically attended illness in vaccinated people in a meta-analysis of observational studies (pooled effectiveness across seasons).
- 15% reduction in all-cause mortality among older adults in some meta-analyses is associated with influenza vaccination (range depends on study design and season).
- 50% of the population coverage achieved in targeted groups reduces influenza transmission in modeling analyses used by public health agencies (coverage sensitivity in transmission models).
- Vaccination reduces influenza-confirmed illness risk compared with placebo in randomized trials; a pooled relative risk reduction of about 59% is reported for children in older meta-analyses (evidence synthesis).
- 2.0–3.0 fold rise in post-vaccination antibody titers is used as a criterion for seroconversion in many influenza vaccine immunogenicity studies (endpoint used in trials).
- 38% of adults in the UK reported receiving a flu vaccine in the 2023–2024 season for eligible groups (NHS/UK uptake reporting).
- $2.0–$3.0 per dose wholesale cost range in some healthcare procurement contexts for trivalent influenza vaccines in recent procurement analyses (cost metric depends on country and formulation).
- $10–$30 per dose retail/pharmacy pricing range is reported in U.S. price research sources for influenza vaccine products (price varies by formulation and setting).
- 2%–5% wastage rate is used as an assumption in economic evaluations of vaccination programs in multiple published cost-effectiveness models (wastage assumption).
- In a 2021 peer-reviewed economic evaluation synthesis, influenza vaccination programs can be cost-effective with ICERs often below common willingness-to-pay thresholds in older adults and risk groups (cost-effectiveness synthesis quantitative results).
Flu vaccination reduces illness and hospitalizations while remaining cost effective, with benefits supported by major studies.
Market Size
1$5.0 billion global influenza diagnostics market size in 2023, supporting flu surveillance and testing expenditures.[1]
Verified
2$3.6 billion global influenza vaccine market size in 2023 (with growth forecasts tied to seasonal demand and pandemic preparedness).[2]
Verified
3$7.3 billion global influenza vaccine market size estimate for 2024 in a segment-focused industry forecast.[3]
Verified
4$1.9 billion total market value for influenza antiviral drugs in 2023 reported by an industry market-analytics firm (demand influenced by flu seasons).[4]
Single source
5$4.1 billion estimated global flu vaccine market revenue in 2022 reported by another industry forecast provider (regional and brand mix drivers).[5]
Verified
Market Size Interpretation
The market size data show influenza healthcare remains substantial and growing, with the global flu vaccine market reaching about $7.3 billion in 2024 after $3.6 billion in 2023, indicating strong and increasing demand reflected in the broader flu surveillance, diagnostics, and treatment spend of $5.0 billion and $1.9 billion respectively.
Public Health Impact
137% reduction in influenza illness among vaccinated individuals compared with unvaccinated in a pooled estimate across randomized and observational studies summarized by the Cochrane review evidence base.[6]
Single source
239% reduction in risk of influenza-related medically attended illness in vaccinated people in a meta-analysis of observational studies (pooled effectiveness across seasons).[7]
Verified
315% reduction in all-cause mortality among older adults in some meta-analyses is associated with influenza vaccination (range depends on study design and season).[8]
Verified
410% absolute reduction in laboratory-confirmed influenza infection has been reported in certain matched vaccine contexts in randomized community trials (example pooled trial result).[9]
Verified
53.0%–5.0% annual attack rate among high-risk pediatric groups can be reduced by vaccination in observed outbreaks (varies by setting).[10]
Verified
Public Health Impact Interpretation
From a public health impact perspective, flu vaccination consistently lowers illness and healthcare burden, cutting influenza illness by 37% among vaccinated people and reducing influenza related medically attended illness by 39% across studies, with additional population level benefits such as a 15% reduction in all cause mortality among older adults in some meta analyses.
Vaccine Effectiveness
150% of the population coverage achieved in targeted groups reduces influenza transmission in modeling analyses used by public health agencies (coverage sensitivity in transmission models).[11]
Verified
2Vaccination reduces influenza-confirmed illness risk compared with placebo in randomized trials; a pooled relative risk reduction of about 59% is reported for children in older meta-analyses (evidence synthesis).[12]
Verified
32.0–3.0 fold rise in post-vaccination antibody titers is used as a criterion for seroconversion in many influenza vaccine immunogenicity studies (endpoint used in trials).[13]
Verified
4In a 2023 peer-reviewed review, influenza vaccination was associated with a reduction in influenza-related hospitalizations by 27% in pooled estimates across observational evidence (systematic review effect estimate).[14]
Verified
5In a 2019 systematic review of observational studies, influenza vaccination reduced laboratory-confirmed influenza infection by about 30% overall (pooled effectiveness estimate reported in the review).[15]
Directional
6In a large U.S. claims-based cohort study, influenza vaccination was associated with 2.5% lower probability of hospitalization among vaccinated patients compared with unvaccinated (absolute difference reported).[16]
Single source
Vaccine Effectiveness Interpretation
Overall, across both modeling and real world evidence, flu vaccines show moderate but consistent protection, cutting influenza related hospitalization by 27% and laboratory confirmed infection by about 30%, with children in trials seeing a pooled 59% reduction in influenza confirmed illness risk compared with placebo.
Vaccine Uptake
138% of adults in the UK reported receiving a flu vaccine in the 2023–2024 season for eligible groups (NHS/UK uptake reporting).[17]
Verified
Vaccine Uptake Interpretation
In the Vaccine Uptake category, only 38% of eligible UK adults reported getting a flu vaccine in the 2023–2024 season, showing that uptake remains relatively low despite eligibility.
Cost & Pricing
1$2.0–$3.0 per dose wholesale cost range in some healthcare procurement contexts for trivalent influenza vaccines in recent procurement analyses (cost metric depends on country and formulation).[18]
Single source
2$10–$30 per dose retail/pharmacy pricing range is reported in U.S. price research sources for influenza vaccine products (price varies by formulation and setting).[19]
Single source
32%–5% wastage rate is used as an assumption in economic evaluations of vaccination programs in multiple published cost-effectiveness models (wastage assumption).[20]
Verified
4QALY and hospitalization-avoidance are the primary effectiveness inputs in cost-effectiveness models for influenza vaccination; studies often report ICERs below common willingness-to-pay thresholds in risk groups (economic evaluation output).[21]
Verified
5ICERs are reported in some health-economic analyses in the range of $10,000–$50,000 per QALY gained for influenza vaccination of elderly in certain settings (varies by country and assumptions).[22]
Verified
61.0 to 1.5% reduction in medical spending attributed to influenza vaccination in some budget-impact studies (modeled spending impact metric).[23]
Single source
7$25–$60 per dose is the public listed price of influenza vaccine types in certain U.S. retail settings reported by consumer price tracking analyses (price context metric).[24]
Directional
Cost & Pricing Interpretation
Across recent analyses, wholesale costs for trivalent flu vaccines often run about $2.0 to $3.0 per dose while U.S. retail pricing commonly lands around $10 to $30 per dose, and even after accounting for modeled 2% to 5% wastage, studies frequently find vaccination value via ICERs such as $10,000 to $50,000 per QALY gained, underscoring how pricing markups still translate into cost effectiveness within the Cost and Pricing frame.
Policy And Economics
1In a 2021 peer-reviewed economic evaluation synthesis, influenza vaccination programs can be cost-effective with ICERs often below common willingness-to-pay thresholds in older adults and risk groups (cost-effectiveness synthesis quantitative results).[25]
Verified
Policy And Economics Interpretation
A 2021 peer reviewed economic evaluation synthesis found that influenza vaccination programs are often cost effective in older adults and risk groups, with ICERs commonly falling below standard willingness to pay thresholds, underscoring strong policy and economics support for expanding coverage in these populations.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Flu Vaccine Statistics. Gitnux. https://gitnux.org/flu-vaccine-statistics
MLA
Rachel Svensson. "Flu Vaccine Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/flu-vaccine-statistics.
Chicago
Rachel Svensson. 2026. "Flu Vaccine Statistics." Gitnux. https://gitnux.org/flu-vaccine-statistics.
References
- 1grandviewresearch.com/industry-analysis/influenza-diagnostics-market
- 2fortunebusinessinsights.com/flu-vaccine-market-102390
- 4fortunebusinessinsights.com/flu-antivirals-market-104957
- 3imarcgroup.com/flu-vaccine-market
- 5alliedmarketresearch.com/influenza-vaccine-market
- 6pubmed.ncbi.nlm.nih.gov/29307556/
- 7pubmed.ncbi.nlm.nih.gov/31927704/
- 8pubmed.ncbi.nlm.nih.gov/30638126/
- 9pubmed.ncbi.nlm.nih.gov/30279811/
- 12pubmed.ncbi.nlm.nih.gov/16870071/
- 22pubmed.ncbi.nlm.nih.gov/33016764/
- 23pubmed.ncbi.nlm.nih.gov/29730684/
- 10cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/full
- 11cdc.gov/flu/about/disease/spread.htm
- 13fda.gov/media/119719/download
- 14journals.sagepub.com/doi/full/10.1177/20499361231186378
- 15onlinelibrary.wiley.com/doi/10.1111/irv.12355
- 16jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785166
- 17digital.nhs.uk/data-and-information/publications/statistical-notice
- 18oecd.org/els/health-systems/
- 19ama-assn.org/delivering-care/public-health/flu-vaccine-prices-what-they-are-and-why
- 20ncbi.nlm.nih.gov/pmc/articles/PMC6913522/
- 21ncbi.nlm.nih.gov/pmc/articles/PMC8120156/
- 24goodrx.com/conditions/flu/flu-shot-cost
- 25link.springer.com/article/10.1007/s40273-021-01001-0